Tecentriq 1200mg is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).
In 2015, it was in clinical trials as an immunotherapy for several types of solid tumors. It was under investigation by Genentech/Roche.
In September 2018, it was announced that Tecentriq prolongs survival in extensive stage small cell lung cancer treatment, according to study results presented at the 19th World Conference on Lung Cancer (WCLC) in Toronto, Canada.
In March 2019, it was approved by the FDA for advanced triple-negative breast cancer treatment.
tecentriq side effects